Search results for "even"

showing 10 items of 5033 documents

Dentists and dietitians: recommendations of snacks and dental caries experience among kindergarteners”

2016

Background Parents receive diet recommendations for their children from dentists and dietitians, but a conflict of diet suggestions has been reported. This research was conducted to investigate dental caries experiences in children consuming snacks that were recommended by dentists and/or dietitians. Material and Methods A total of 442 kindergarteners under went dental examinations, and their caregivers filled out questionnaires. Snacks were sorted by name. Three dentists and three dietitians determined whether they would recommend these snacks. The snacks were divided into four categories: snacks recommended by both groups, snacks recommended by neither, snacks recommended only by dentists…

0301 basic medicinemedicine.medical_specialtyDieticiansDentistryOdontologíaDental examinationsNutrient density03 medical and health sciences0302 clinical medicineMedicineGeneral Dentistry2. Zero hunger030109 nutrition & dieteticsbusiness.industryResearchdigestive oral and skin physiologyfood and beverages030206 dentistryCiencias de la saludCommunity and Preventive Dentistry3. Good healthFamily medicineUNESCO::CIENCIAS MÃ DICAS:CIENCIAS MÃ DICAS [UNESCO]businessCaries experiencehuman activities
researchProduct

Neurotrophic and neuroprotective effects of muscle contraction

2016

Background: Physical activity has been shown to be associated with reduced risk of coronary heart disease but the same effect seems to be produced in neurological diseases. Objective: In this review, we focused on the interplay between physical activity and some neurological conditions (Stroke, dementia, epilepsy, headache, Parkinson’ s disease, amyotrophic lateral sclerosis, multiple sclerosis, insomnia, depression and anxiety) with the aim of describing the potential role of physical activity in the prevention of such diseases and the physiological mechanisms involved in these processes. Results: Despite a growing body of evidence which reveals that physical activity is able to reduce the…

0301 basic medicinemedicine.medical_specialtyDiseaseBioinformaticsNeuroprotection03 medical and health sciencesEpilepsyPhysical medicine and rehabilitationDrug DiscoverymedicineHumansDementiaNervous System Physiological PhenomenaAmyotrophic lateral sclerosisStrokeExerciseLife StyleNervous System DiseaseDepression (differential diagnoses)EndocannabinoidPharmacologybusiness.industryPhysical activityMultiple sclerosisPreventionBrain-Derived Neurotrophic FactorRehabilitationOxidative Stremedicine.diseaseLifestyleStrokeOxidative Stress030104 developmental biologyCerebrovascular CirculationDementiaNervous System DiseasesbusinessNeurological diseaseEndocannabinoidsHumanMuscle Contraction
researchProduct

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or me…

2020

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. Patients and methods Eligible patients with confirmed ESCC that was not curatively resectable or did not qualify for definitive radiochemotherapy, were randomised 1 : 1 to receive CF [cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1–4] or CF plus P (9…

0301 basic medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentPopulationMedizinGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicinePanitumumabHumansProspective StudieseducationCisplatineducation.field_of_studyChemotherapybusiness.industryPanitumumabHazard ratioCommon Terminology Criteria for Adverse EventsHematologymedicine.diseaseErbB Receptors030104 developmental biologyTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisCarcinoma Squamous CellFluorouracilCisplatinbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations

2016

International audience; AIMS: Mutations in PRKAG2, the gene encoding for the γ2 subunit of 5'-AMP-activated protein kinase (AMPK), are responsible for an autosomal dominant glycogenosis with a cardiac presentation, associating hypertrophic cardiomyopathy (HCM), ventricular pre-excitation (VPE), and progressive heart block. The aim of this study was to perform a retrospective time-to-event study of the clinical manifestations associated with PRKAG2 mutations.METHODS AND RESULTS: A cohort of 34 patients from 9 families was recruited between 2001 and 2010. DNA were sequenced on all exons and flanking sequences of the PRKAG2 gene using Sanger sequencing. Overall, four families carried the recur…

0301 basic medicinemedicine.medical_specialtyHeart blockCardiomyopathymedicine.medical_treatmentCardiomyopathyDisease030204 cardiovascular system & hematologySudden cardiac deathTime-to-event study03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPhysiology (medical)Internal medicineWolff–Parkinson–WhiteVentricular pre-excitationmedicineHeart transplantationbusiness.industryIncidence (epidemiology)Hypertrophic cardiomyopathy[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasePRKAG23. Good health030104 developmental biologyCohortCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Benefits of the Mediterranean diet: Epidemiological and molecular aspects

2019

Abstract More than 50 years after the Seven Countries Study, a large number of epidemiological studies have explored the relationship between the Mediterranean diet (MD) and health, through observational, case-control, some longitudinal and a few experimental studies. The overall results show strong evidence suggesting a protective effect of the MD mainly on the risk of cardiovascular disease (CVD) and certain types of cancer. The beneficial effects have been attributed to the types of food consumed, total dietary pattern, components in the food, cooking techniques, eating behaviors and lifestyle behaviors, among others. The aim of this article is to review and summarize the knowledge deriv…

0301 basic medicinemedicine.medical_specialtyMediterranean dietClinical BiochemistryDiseaseDiet MediterraneanBiochemistrylaw.invention03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled triallawSeven Countries StudyNeoplasmsEnvironmental healthEpidemiologymedicineHumansMetabolomicsMolecular BiologyRandomized Controlled Trials as Topicbusiness.industryGeneral MedicineMental healthEpidemiologic StudiesObservational Studies as Topic030104 developmental biologyCardiovascular Diseases030220 oncology & carcinogenesisMolecular MedicineObservational studybusinessBiomarkersMolecular Aspects of Medicine
researchProduct

Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?

2016

Traumatic brain injury (TBI) is a leading cause of death and disability in the modern society. Although primary prevention is the only strategy that can counteract the primary brain damage, numerous preclinical studies have been accumulated in order to find therapeutic strategies against the secondary damage. In this scenario erythropoietin (EPO) has been shown to be a promising candidate as neuroprotective agent. A recent clinical trial, however, has shown that EPO has not an overall effect on outcomes following TBI thus renewing old concerns.  However, the results of a prespecified sensitivity analysis indicate that the effect of EPO on mortality remains still unclear. In the light of the…

0301 basic medicinemedicine.medical_specialtyMolecular PharmacologyNeuropharmacology & PsychopharmacologyTraumatic brain injurySolid baseBrain damageNeuroprotectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTraumatic brain injury0302 clinical medicinePrimary preventionmedicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineErythropoietin; Neuroprotection; Traumatic brain injuryErythropoietinCause of deathGeneral Immunology and Microbiologybusiness.industryArticlesGeneral MedicineOpinion Articlemedicine.diseaseNeuroprotectionClinical trial030104 developmental biologyErythropoietinmedicine.symptombusinessNeuroscience030217 neurology & neurosurgerymedicine.drugF1000Research
researchProduct

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

2019

International audience; Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in association with oth…

0301 basic medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]PlaceboMusculoskeletal disorderslaw.invention03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled triallawInternal medicineNon-musculoskeletal adverse eventmedicineRed yeast riceHumansMusculoskeletal DiseasesAdverse effectRandomized Controlled Trials as TopicPharmacologyBiological Productsbusiness.industryMusculoskeletal disorderOdds ratioNon-musculoskeletal adverse eventsSerious adverse events[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good health[SDV] Life Sciences [q-bio]Clinical trial030104 developmental biologyRed yeast riceTolerability030220 oncology & carcinogenesisMeta-analysisDietary SupplementsSafetybusinessPharmacological research
researchProduct

Update and guidance on management of myopia : European Society of Ophthalmology in cooperation with International Myopia Institute

2021

The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, t…

0301 basic medicinemedicine.medical_specialtygenetic structuresmedicine.medical_treatmentatropinePsychological interventionReviewsorthokeratologylikinäköisyyspreventive medicineehkäisevä lääketiede03 medical and health sciences0302 clinical medicineOphthalmologynäkövammatEpidemiologyMyopiaPrevalenceMedicineHumansmyopiaPreventive healthcareBlindnessbusiness.industrypathologic myopiaPathological myopiaOrthokeratologyHigh myopiaTreatment optionsGeneral Medicinemedicine.diseasetime spent outdoorsmyopia reduction interventionsMyopia Degenerative/epidemiologyeye diseasesOphthalmology030104 developmental biologyMyopia Degenerativesilmätaudit030221 ophthalmology & optometryDisease Progressionsense organsbusinessOrthokeratologic Proceduresblindnesssokeus
researchProduct